BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19513067)

  • 1. Quantitative immunohistochemical expression of c Kit in breast carcinomas is predictive of patients' outcome.
    Charpin C; Giusiano S; Charfi S; Secq V; Carpentier S; Andrac L; Lavaut MN; Allasia C; Bonnier P; Garcia S
    Br J Cancer; 2009 Jul; 101(1):48-54. PubMed ID: 19513067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical profiling of node negative breast carcinomas allows prediction of metastatic risk.
    Giusiano S; Secq V; Carcopino X; Carpentier S; Andrac L; Lavaut MN; Allasia C; Bonnier P; Iovanna JL; Garcia S; Boubli L; Birnbaum D; Charpin C
    Int J Oncol; 2010 Apr; 36(4):889-98. PubMed ID: 20198333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein kinase CK2α subunit over-expression correlates with metastatic risk in breast carcinomas: quantitative immunohistochemistry in tissue microarrays.
    Giusiano S; Cochet C; Filhol O; Duchemin-Pelletier E; Secq V; Bonnier P; Carcopino X; Boubli L; Birnbaum D; Garcia S; Iovanna J; Charpin C
    Eur J Cancer; 2011 Mar; 47(5):792-801. PubMed ID: 21194925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-kit expression in high-risk breast cancer subgroup treated with high-dose or conventional dose-dense chemotherapy.
    Diallo R; Ting E; Gluz O; Herr A; Schütt G; Geddert H; Mohrmann S; Gabbert HE; Nitz U; Poremba C
    Verh Dtsch Ges Pathol; 2006; 90():177-85. PubMed ID: 17867595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer.
    Kashiwagi S; Yashiro M; Takashima T; Aomatsu N; Kawajiri H; Ogawa Y; Onoda N; Ishikawa T; Wakasa K; Hirakawa K
    Br J Surg; 2013 Mar; 100(4):490-6. PubMed ID: 23319435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays.
    Charpin C; Secq V; Giusiano S; Carpentier S; Andrac L; Lavaut MN; Allasia C; Bonnier P; Garcia S
    Int J Cancer; 2009 May; 124(9):2124-34. PubMed ID: 19142869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Early breast carcinoma profiling based on quantitative immunocytochemistry can help predict the risk of early distant metastasis].
    Taranger-Charpin C; Giusiano S; Secq V; Djemli A; Andrac L; Lavaut MN; Allasia C; Garcia S
    Bull Acad Natl Med; 2009 Dec; 193(9):2045-60; discussion 2060-1. PubMed ID: 20666017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of C-KIT and HER-2 tyrosine kinase receptors in poor-prognosis breast cancer.
    Palmu S; Söderström KO; Quazi K; Isola J; Salminen E
    Anticancer Res; 2002; 22(1A):411-4. PubMed ID: 12017324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-kit (CD117) expression in human tumors and its prognostic value: an immunohistochemical analysis.
    Medinger M; Kleinschmidt M; Mross K; Wehmeyer B; Unger C; Schaefer HE; Weber R; Azemar M
    Pathol Oncol Res; 2010 Sep; 16(3):295-301. PubMed ID: 20177846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients.
    Esteban JM; Felder B; Ahn C; Simpson JF; Battifora H; Shively JE
    Cancer; 1994 Sep; 74(5):1575-83. PubMed ID: 7914825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NEDD4 expression is associated with breast cancer progression and is predictive of a poor prognosis.
    Wan L; Liu T; Hong Z; Pan Y; Sizemore ST; Zhang J; Ma Z
    Breast Cancer Res; 2019 Dec; 21(1):148. PubMed ID: 31856858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative immunocytochemical profile to predict early outcome of disease in triple-negative breast carcinomas.
    Charpin C; Giusiano S; Secq V; Carpentier S; Andrac L; Lavaut MN; Allasia C; Bonnier P; Garcia S
    Int J Oncol; 2009 Apr; 34(4):983-93. PubMed ID: 19287955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients.
    Rivadeneira DE; Simmons RM; Christos PJ; Hanna K; Daly JM; Osborne MP
    J Am Coll Surg; 2000 Jul; 191(1):1-6; discussion 6-8. PubMed ID: 10898177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer.
    Zhang B; Cao X; Liu Y; Cao W; Zhang F; Zhang S; Li H; Ning L; Fu L; Niu Y; Niu R; Sun B; Hao X
    BMC Cancer; 2008 Mar; 8():83. PubMed ID: 18373849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LEA.135 expression: an independent and favorable prognostic biomarker for patients with primary invasive breast cancer.
    Liu D; Naritoku WY; Tsao-Wei D; Groshen S; Neville MA; Taylor CR; Cote RJ; Imam SA
    Int J Cancer; 2000 May; 89(3):224-9. PubMed ID: 10861497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival.
    Charpin C; Garcia S; Bouvier C; Martini F; Lavaut MN; Allasia C; Bonnier P; Andrac L
    Br J Cancer; 1997; 75(11):1667-73. PubMed ID: 9184184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of c-kit and ki-67 expression on patients prognosis in advanced ovarian serous carcinoma.
    Khalifeh I; Munkarah AR; Schimp V; Morris R; Lawrence WD; Ali-Fehmi R
    Int J Gynecol Pathol; 2005 Jul; 24(3):228-34. PubMed ID: 15968197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value of lymphatic and blood vessel invasion in operable breast cancer.
    Lauria R; Perrone F; Carlomagno C; De Laurentiis M; Morabito A; Gallo C; Varriale E; Pettinato G; Panico L; Petrella G
    Cancer; 1995 Nov; 76(10):1772-8. PubMed ID: 8625046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer.
    Harigopal M; Berger AJ; Camp RL; Rimm DL; Kluger HM
    Clin Cancer Res; 2005 Jun; 11(11):4083-9. PubMed ID: 15930343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysozyme expression by breast carcinomas, correlation with clinicopathologic parameters, and prognostic significance.
    Vizoso F; Plaza E; Vázquez J; Serra C; Lamelas ML; González LO; Merino AM; Méndez J
    Ann Surg Oncol; 2001 Sep; 8(8):667-74. PubMed ID: 11569783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.